Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.76 USD | +2.40% | -0.34% | +124.90% |
May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+124.90% | 598M | |
+23.30% | 44.96B | |
+1.03% | 42.65B | |
+46.11% | 41.85B | |
-4.27% | 29.04B | |
+10.74% | 26.08B | |
-20.62% | 19.03B | |
+5.72% | 12.75B | |
+28.14% | 12.06B | |
-4.03% | 11.75B |
- Stock Market
- Equities
- STOK Stock
- News Stoke Therapeutics, Inc.
- Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating